Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option and Sells Shares Under 10b5-1 Plan

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On March 27, 2025, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 3,250 shares of common stock at a weighted average price of $21.3295, with individual sales prices ranging from $20.75 to $21.645.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 23,000 shares of Enliven Therapeutics common stock and holds options for 128,556 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan indicates that the insider's trading activity was pre-planned and not based on any material non-public information at the time of the trades.

Stakeholder Impact

• Shareholders may interpret insider transactions as a signal of management's confidence (or lack thereof) in the company's future performance.
• The use of a 10b5-1 plan provides some reassurance that the transactions were not based on insider information.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Insider Trading